These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 28817201)

  • 1. Exposure-Response Modeling and Power Analysis of Components of ACR Response Criteria in Rheumatoid Arthritis (Part 2: Continuous Model).
    Li L; Zhang Y; Ma L; Ji P; Yim S; Chowdhury BA; Doddapaneni S; Liu J; Wang Y; Sahajwalla C
    J Clin Pharmacol; 2017 Sep; 57(9):1107-1125. PubMed ID: 28817201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exposure-Response Modeling and Power Analysis of Components of ACR Response Criteria in Rheumatoid Arthritis (Part 1: Binary Model).
    Li L; Zhang Y; Ma L; Ji P; Yim S; Chowdhury B; Doddapaneni S; Liu J; Wang Y; Sahajwalla C
    J Clin Pharmacol; 2017 Sep; 57(9):1097-1106. PubMed ID: 28817199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group.
    Tugwell P; Wells G; Strand V; Maetzel A; Bombardier C; Crawford B; Dorrier C; Thompson A
    Arthritis Rheum; 2000 Mar; 43(3):506-14. PubMed ID: 10728742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous indices of core data set measures in rheumatoid arthritis clinical trials: lower responses to placebo than seen with categorical responses with the American College of Rheumatology 20% criteria.
    Pincus T; Amara I; Koch GG
    Arthritis Rheum; 2005 Apr; 52(4):1031-6. PubMed ID: 15818698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate.
    Genovese MC; Lee E; Satterwhite J; Veenhuizen M; Disch D; Berclaz PY; Myers S; Sides G; Benichou O
    Ann Rheum Dis; 2013 Sep; 72(9):1453-60. PubMed ID: 23599435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelling the cost-effectiveness of combination therapy for early, rapidly progressing rheumatoid arthritis by simulating the reversible and irreversible effects of the disease.
    Stephens S; Botteman MF; Cifaldi MA; van Hout BA
    BMJ Open; 2015 Jun; 5(6):e006560. PubMed ID: 26059521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of etanercept dose reduction in patients with rheumatoid arthritis using pharmacokinetic/pharmacodynamic modeling and simulation.
    Hsu LF; Huang JD
    Int J Clin Pharmacol Ther; 2014 Sep; 52(9):776-86. PubMed ID: 24887337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Good response to infliximab in rheumatoid arthritis following failure of interleukin-1 receptor antagonist.
    Bao J; Yue T; Li T; He DY; Bao YX
    Int J Rheum Dis; 2016 Apr; 19(4):370-6. PubMed ID: 24798350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A psychometric analysis of outcome measures in peripheral spondyloarthritis.
    Turina MC; Ramiro S; Baeten DL; Mease P; Paramarta JE; Song IH; Pangan AL; Landewé R
    Ann Rheum Dis; 2016 Jul; 75(7):1302-7. PubMed ID: 26245756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
    Smolen JS; Han C; Bala M; Maini RN; Kalden JR; van der Heijde D; Breedveld FC; Furst DE; Lipsky PE;
    Arthritis Rheum; 2005 Apr; 52(4):1020-30. PubMed ID: 15818697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial.
    Pincus T; Strand V; Koch G; Amara I; Crawford B; Wolfe F; Cohen S; Felson D
    Arthritis Rheum; 2003 Mar; 48(3):625-30. PubMed ID: 12632413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomized, placebo-controlled study.
    Lan JL; Chou SJ; Chen DY; Chen YH; Hsieh TY; Young M
    J Formos Med Assoc; 2004 Aug; 103(8):618-23. PubMed ID: 15340661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term outcome after anti-tumor necrosis factor-alpha therapy in rheumatoid arthritis: do we need to revise our assessment criteria?
    El Miedany Y; Youssef SS; El Gaafary M
    J Rheumatol; 2006 Mar; 33(3):490-7. PubMed ID: 16511918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exposure-response modeling of peficitinib efficacy in patients with rheumatoid arthritis.
    Toyoshima J; Kaibara A; Shibata M; Kaneko Y; Izutsu H; Nishimura T
    Pharmacol Res Perspect; 2021 May; 9(3):e00744. PubMed ID: 33929089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levofloxacin treatment in patients with rheumatoid arthritis receiving methotrexate.
    Ogrendik M
    South Med J; 2007 Feb; 100(2):135-9. PubMed ID: 17330681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicentre observational study comparing patient reported outcomes to assess reliability of swollen and tender joint assessments and response to certolizumab treatment as compared to clinician assessments in rheumatoid arthritis.
    Inderjeeth CA; Inderjeeth AJ; Raymond WD
    Int J Rheum Dis; 2019 Jan; 22(1):73-80. PubMed ID: 30187688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Joint longitudinal model development: application to exposure-response modeling of ACR and DAS scores in rheumatoid arthritis patients treated with sirukumab.
    Hu C; Xu Y; Zhuang Y; Hsu B; Sharma A; Xu Z; Zhang L; Zhou H
    J Pharmacokinet Pharmacodyn; 2018 Oct; 45(5):679-691. PubMed ID: 29961161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exposure-response relationship of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in a large population of patients with rheumatoid arthritis.
    Levi M; Grange S; Frey N
    J Clin Pharmacol; 2013 Feb; 53(2):151-9. PubMed ID: 23436260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical endpoint sensitivity in rheumatoid arthritis: modeling and simulation.
    Ma L; Zhao L; Xu Y; Yim S; Doddapaneni S; Sahajwalla CG; Wang Y; Ji P
    J Pharmacokinet Pharmacodyn; 2014 Oct; 41(5):537-43. PubMed ID: 25283268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative efficiencies of the 7 rheumatoid arthritis Core Data Set measures to distinguish active from control treatments in 9 comparisons from clinical trials of 5 agents.
    Pincus T; Richardson B; Strand V; Bergman MJ
    Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-47-54. PubMed ID: 25365089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.